Somatostatin inhibits insulin-stimulated gastrin release and gastric secretion of acid, pepsin, and intrinsic factor (IF) in duodenal ulcer patients.
The effect os somatostatin (0.6 mg/hour) on insulin-stimulated gastrin release and gastric secretion of acid, pepsin, and IF has been examined in 6 unoperated patients with duodenal ulcer. Gastrin release and gastric secretion of acid, pepsin, and IF in response to insulin alone (0.15 IU/kg bw. iv.) were significantly reduced by simultaneous administration of somatostatin. This finding indicates an inhibitory effect of somatostatin on insulin-induced gastrin release and gastrin secretion in addition to the already known effects of somatostatin.
D001786:Blood Glucose / Q000378:metabolism; D004347:Drug Interactions; D004381:Duodenal Ulcer / Q000097:blood / Q000503:physiopathology*; D005750:Gastric Juice / Q000378:metabolism*; D005755:Gastrins / Q000378:metabolism*; D006801:Humans; D007328:Insulin / Q000494:pharmacology*; D007329:Insulin Antagonists; D007437:Intrinsic Factor / Q000378:metabolism*; D010418:Pentagastrin; D010434:Pepsin A / Q000378:metabolism*; D012636:Secretory Rate / Q000187:drug effects; D013004:Somatostatin / Q000494:pharmacology*
D001786:Blood Glucose; D005755:Gastrins; D007328:Insulin; D007329:Insulin Antagonists; D013004:Somatostatin; D007437:Intrinsic Factor; D010434:Pepsin A; D010418:Pentagastrin